IMMX ▲ +3.1% - Immix Biopharma, Inc.
$IMMX - Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
04-NOV-2026 09:15 AM ET
Share this post
More filings for $IMMX
IMMX - Immix Biopharma, Inc. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026IMMX ▼ -0.2% - Immix Biopharma, Inc.Oct 5, 2026IMMX ▼ -2.8% - Immix Biopharma, Inc.Sep 30, 2026IMMX ▲ +5.5% - Immix Biopharma, Inc.Sep 29, 2026IMMX ▲ +5.5% - Immix Biopharma, Inc.Sep 29, 2026IMMX - Immix Biopharma, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $IMMX filing history →💬 Comments
Loading comments…
Leave a comment